Rush University CRS – ACTG Network

Location	600 South Paulina Street, Suite 140 Chicago, IL 60612 United States of America
Phone	(312) 942-4810
CRS Coordinator	Mark Mall mark_mall@rush.edu 312-942-5865
CRS Leader	Beverly Sha beverly_sha@rush.edu 312-942-5865
Studies	A5128: US Genomic Sampling A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study A5345: HIV Rebound & Control Biomarkers A5354: Early ART in Acute HIV A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults A5359: The LATITUDE Study A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5369: p24CE Vaccine Study A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) A5332: REPRIEVE Trial A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)